Ballen Karen K, Becker Pamela S, Yeap Beow Yong, Matthews Barbara, Henry David H, Ford Patricia A
Division of Hematology/Oncology, Massachusetts General Hospital, 100 Blossom St, Cox 640, Boston, MA 02114, USA.
J Clin Oncol. 2004 Oct 15;22(20):4087-94. doi: 10.1200/JCO.2004.01.144. Epub 2004 Sep 7.
Autologous stem-cell transplantation has been shown to be a curative procedure for a variety of leukemias and lymphomas. Most transplants require RBC and platelet support. We report the ability to perform autologous transplantation without blood-product support.
In this study, we treated 26 patients with religious objection to blood products with autologous stem-cell support without the use of any blood products. Patients received a combination of granulocyte colony-stimulating factor (G-CSF), erythropoietin, and interleukin-11 or G-CSF alone to mobilize stem cells. Post-transplant patients received intravenous iron, erythropoietin, G-CSF, and epsilon aminocaproic acid.
There were two major bleeding complications (8%), with two treatment-related deaths (8%). There were three minor bleeding complications (12%). The median fall in hemoglobin level was 4.7 g/dL; the median hemoglobin level 30 days after transplantation was 9.2 g/dL. The median total number of days with platelet count less than 10 x 10(9)/L was 4 days; the median days to platelet recovery greater than 20 x 10(9)/L was 12 days.
Autologous stem-cell transplantation can be performed safely without the use of any blood products.
自体干细胞移植已被证明是治疗多种白血病和淋巴瘤的有效方法。大多数移植需要红细胞和血小板支持。我们报告了在不使用血液制品支持的情况下进行自体移植的能力。
在本研究中,我们对26名因宗教原因反对使用血液制品的患者进行了自体干细胞支持治疗,且未使用任何血液制品。患者接受粒细胞集落刺激因子(G-CSF)、促红细胞生成素和白细胞介素-11的联合治疗或仅接受G-CSF以动员干细胞。移植后患者接受静脉铁剂、促红细胞生成素、G-CSF和ε-氨基己酸治疗。
发生了2例严重出血并发症(8%),2例与治疗相关的死亡(8%)。有3例轻微出血并发症(12%)。血红蛋白水平的中位数下降了4.7 g/dL;移植后30天的血红蛋白水平中位数为9.2 g/dL。血小板计数低于10×10⁹/L的总天数中位数为4天;血小板恢复至大于20×10⁹/L的天数中位数为12天。
不使用任何血液制品也可安全地进行自体干细胞移植。